Company intelligence / Profile preview

BioPredictive

Paris, Île-de-France, France

Ownership: Private
Development stage: Other

Overview

BioPredictive’s tests, centered on FibroTest and bundled solutions, are non-invasive, validated in >300 clinical trials, and widely adopted as alternatives to liver biopsy for diagnosing and staging various liver diseases in routine clinical practice.

Therapeutic areas: ImmunologyInfectious DiseasesHematologyGastroenterology
Modalities: Diagnostic testAlgorithm-based blood test
Industry: Molecular Diagnostics

Partnerships

LabCorp (distribution of FibroTest under the brand "FibroSure" in the US)Major North American laboratories (distribution partners)

Beyond the preview

Go deeper on BioPredictive.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioPredictive.

Explore the full profile